Literature DB >> 9368073

Characterization of the reovirus lambda1 protein RNA 5'-triphosphatase activity.

M Bisaillon1, G Lemay.   

Abstract

Characterization of the phosphohydrolytic activities of recombinant reovirus lambda1 protein demonstrates that, in addition to the previously reported nucleoside triphosphate phosphohydrolase and helicase activities, the protein also possesses RNA 5'-triphosphatase activity. This activity was absolutely dependent on the presence of a divalent cation, Mg2+ or Mn2+, and specifically removes the 5'-gamma-phosphate at the end of triphosphate-terminated RNAs. Kinetic competition analysis showed that nucleoside triphosphate phosphohydrolase and RNA 5'-triphosphatase reactions are carried out at a common active site. These results strongly support the idea that, in addition to its role as an RNA helicase during transcription of the viral genome, lambda1 also participates during formation of the cap structure at the 5' end of newly synthesized reovirus mRNAs. The lambda1 protein represents only the third RNA triphosphatase whose primary structure is known and the first described in a double-stranded RNA virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368073     DOI: 10.1074/jbc.272.47.29954

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  The hydrophilic amino-terminal arm of reovirus core shell protein lambda1 is dispensable for particle assembly.

Authors:  Jonghwa Kim; Xing Zhang; Victoria E Centonze; Valorie D Bowman; Simon Noble; Timothy S Baker; Max L Nibert
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Reovirus polymerase lambda 3 localized by cryo-electron microscopy of virions at a resolution of 7.6 A.

Authors:  Xing Zhang; Stephen B Walker; Paul R Chipman; Max L Nibert; Timothy S Baker
Journal:  Nat Struct Biol       Date:  2003-11-09

3.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure.

Authors:  Moheshwarnath Issur; Brian J Geiss; Isabelle Bougie; Frédéric Picard-Jean; Simon Despins; Joannie Mayette; Sarah E Hobdey; Martin Bisaillon
Journal:  RNA       Date:  2009-10-22       Impact factor: 4.942

5.  A yeast-based genetic system for functional analysis of viral mRNA capping enzymes.

Authors:  C K Ho; A Martins; S Shuman
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Structure of RNA polymerase complex and genome within a dsRNA virus provides insights into the mechanisms of transcription and assembly.

Authors:  Xurong Wang; Fuxian Zhang; Rui Su; Xiaowu Li; Wenyuan Chen; Qingxiu Chen; Tao Yang; Jiawei Wang; Hongrong Liu; Qin Fang; Lingpeng Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

7.  The helicase-like domain of plant potexvirus replicase participates in formation of RNA 5' cap structure by exhibiting RNA 5'-triphosphatase activity.

Authors:  Y I Li; T W Shih; Y H Hsu; Y T Han; Y L Huang; M Meng
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  RNA 5'-triphosphatase activity of the hepatitis E virus helicase domain.

Authors:  Yogesh A Karpe; Kavita S Lole
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

9.  Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.

Authors:  Adil Mohamed; James R Smiley; Maya Shmulevitz
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

10.  Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase.

Authors:  Konstantin A Ivanov; Volker Thiel; Jessika C Dobbe; Yvonne van der Meer; Eric J Snijder; John Ziebuhr
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.